What’s Cabot’s “Small Cap Medical Juggernaut?”

Solving a teaser pitch for the Friday File, plus a checkin on some REITs

By Travis Johnson, Stock Gumshoe, June 10, 2016

Timothy Lutts is hinting at a new small cap stock in order to tantalize potential subscribers to Cabot Small-Cap Confidential 2.0 (which will run you $950/year), and the line that caught my eye was “A Rare Second Chance to Turn $5,000 into $40,000.”

That’s a reference to Tesla, which had such an 800% jump (over 2-1/2 years), and they make those kinds of comparisons all the time in their teaser ads — Cabot is generally a growth-focused publisher, and they use lines like “looks a lot like Tesla/Monster Beverage/Intuitive Surgical” to sell a great many of their ideas… so I wouldn’t take that Tesla comparison terribly literally, but I’m still curious to see who they’re recommending.

This newsletter, by the way, has been pretty quiet on the marketing front recently — they haven’t caught my attention in a couple years, not since they were pitching Cardiovascular Solutions (CSII) as the “stock of the decade” back in 2014. That was a different editor (Thomas Garrity, who is no longer with Cabot), and they’ve apparently moved on and “relaunched” the newsletter as version 2.0 with Tyler Laundon at the helm at some point in the last six months or so (he worked on a few newsletters for Ian Wyatt before moving to Cabot), but it’s still a letter that looks for “undiscovered companies with compelling stories.”

Laundon wasn’t the “name” guy behind many teaser stocks that we covered for Wyatt’s newsletters, so we don’t know a lot about what his favorite promoted picks have done (most of them that I spot checked are pretty flat over the past few years), but you can see some of our articles about his past ideas here if you’re interested in checking up on him. What’s he talking up today?

“Why My Newest Recommendation Looks a Lot Like Tesla in the Early Days

“Just as Tesla‚Äôs battery breakthrough revolutionized the electric car industry, this small cap medical juggernaut is doing the same thing for the surgical treatment of cardio vascular diseases (CVD).

“With 20 million people worldwide suffering from CVD this is one medical stock on a growth trajectory that could easily surpass the big profits we made in Tesla.”

OK, so that provides some worry that they’re just again teasing Cardiovascular Solutions… but given the recent performance of that stock (it’s had a bad year), that’s probably not the case. Let’s ...

Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

Sign Up for a Premium Membership

To view the rest of this article (and to have full access to the rest of our articles), sign up.
Already a member, log in.

Become a member